Skip to content

Prevention of early mortality by presumptive TB treatment [retrospectively registered]

Prevention of early mortality by presumptive TB treatment in HIVinfected

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201110000301425
Enrollment
334
Registered
2011-06-06
Start date
2011-07-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS Tuberculosis

Interventions

ART only
TB medication + ART

Sponsors

Academic Medical Center, University of Amsterdam
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: At least 18 years of age. HIV-1 infected as documented and confirmed by a licensed rapid test for HIV-1 antibodies or HIV-1 antibody ELISA. Eligible for antiretroviral treatment with CD4 T cell count<50 cells/µl. BMI <18 kg/m2 Ability to understand and provide written informed consent for the study.

Exclusion criteria

Exclusion criteria: Patient has smear-positive pulmonary TB. Fulfills the diagnostic criteria for smear-negative pulmonary or extrapulmonary TB. Previous TB treatment (history of TB medication for >1 month. History of using antiretroviral drugs (except short course pMTCT). Symptomatic known underlying liver disease or transaminases >5x upper limit of normal. Known or suspected drug resistance to more than one first-line TB drug (e.g. household contacts of MDR-TB patients). Pregnant or breast-feeding. Cryptococcal meningitis (CrAG positive with neurologic symptoms). Creatinine clearance 30 per minute, heart rate>120bpm, temperature>39oC, unable to ambulate)(requiring empiric antibiotics). Taking other potentially life-saving medications (e.g. for other OIs, or immunosuppressants) that are incompatible with anti-TB chemotherapy or ART. Unable to swallow TB medications. Unable to follow-up at the clinic for regularly scheduled visits (e.g. too far from clinic).

Design outcomes

Primary

MeasureTime frame
¿All-cause mortality in the first 24 weeks after initiation of ART

Secondary

MeasureTime frame
Pulmonary TB (based on available clinical and laboratory information including smear examination, culture, chest X-ray, and clinical assessment);unmasking TB ;sensitivity and specificity of clinical predictors (symptoms, signs, laboratory parameters) for incident unmasking TB;causes of death

Countries

Gabon, Mozambique, South Africa, Uganda

Contacts

Public ContactFrank Cobelens

Professor of International Health

f.cobelens@aighd.org+31205667800

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026